CONTEXT: Impaired vitamin D metabolism may contribute to the development and progression of diabetic kidney disease. OBJECTIVE: The aim of the study was to test associations of circulating vitamin D metabolites with risks of incident microalbuminuria, impaired glomerular filtration rate (GFR), and hypertension in type 1 diabetes. DESIGN: We performed a cohort study of 1193 participants in the Diabetes Control and Complications Trial (DCCT), a randomized clinical trial of intensive diabetes therapy, and its observational follow-up, the Epidemiology of Diabetes Interventions and Complications (EDIC) Study. We measured plasma concentrations of 25-hydroxyvitamin D [25(OH)D], 1,25-dihydroxyvitamin D, and 24,25-dihydroxyvitamin D by mass spectrometry at the end of the DCCT and tested associations with incident microalbuminuria, impaired GFR, and hypertension over up to 16 yr of EDIC follow-up. RESULTS: At the time metabolites were measured, mean age was 32.4 yr; mean duration of diabetes, 7.5 yr; mean iothalamate GFR, 132.9 ml/min/1.73 m(2); and geometric mean albumin excretion rate, 11.8 mg/24 h. Over follow-up, 166 cases of microalbuminuria, 54 cases of impaired GFR, and 541 cases of hypertension were observed. Compared with 25(OH)D of at least 30 ng/ml, 25(OH)D below 20 ng/ml was associated with a 65% higher risk of microalbuminuria (95% confidence interval, 7 to 154%) in adjusted analyses. Low concentrations of 24,25-dihydroxyvitamin D, but not 1,25-dihydroxyvitamin D, were also associated with increased risk of microalbuminuria. No circulating vitamin D metabolite was associated with risk of impaired GFR or hypertension. CONCLUSIONS: Low plasma concentrations of 25(OH)D and 24,25-dihydroxyvitamin D are associated with increased risk of microalbuminuria in type 1 diabetes. In contrast, we did not find evidence linking impaired vitamin D metabolism to early GFR loss or the development of hypertension.
RCT Entities:
CONTEXT: Impaired vitamin D metabolism may contribute to the development and progression of diabetic kidney disease. OBJECTIVE: The aim of the study was to test associations of circulating vitamin D metabolites with risks of incident microalbuminuria, impaired glomerular filtration rate (GFR), and hypertension in type 1 diabetes. DESIGN: We performed a cohort study of 1193 participants in the Diabetes Control and Complications Trial (DCCT), a randomized clinical trial of intensive diabetes therapy, and its observational follow-up, the Epidemiology of Diabetes Interventions and Complications (EDIC) Study. We measured plasma concentrations of 25-hydroxyvitamin D [25(OH)D], 1,25-dihydroxyvitamin D, and 24,25-dihydroxyvitamin D by mass spectrometry at the end of the DCCT and tested associations with incident microalbuminuria, impaired GFR, and hypertension over up to 16 yr of EDIC follow-up. RESULTS: At the time metabolites were measured, mean age was 32.4 yr; mean duration of diabetes, 7.5 yr; mean iothalamate GFR, 132.9 ml/min/1.73 m(2); and geometric mean albumin excretion rate, 11.8 mg/24 h. Over follow-up, 166 cases of microalbuminuria, 54 cases of impaired GFR, and 541 cases of hypertension were observed. Compared with 25(OH)D of at least 30 ng/ml, 25(OH)D below 20 ng/ml was associated with a 65% higher risk of microalbuminuria (95% confidence interval, 7 to 154%) in adjusted analyses. Low concentrations of 24,25-dihydroxyvitamin D, but not 1,25-dihydroxyvitamin D, were also associated with increased risk of microalbuminuria. No circulating vitamin D metabolite was associated with risk of impaired GFR or hypertension. CONCLUSIONS: Low plasma concentrations of 25(OH)D and 24,25-dihydroxyvitamin D are associated with increased risk of microalbuminuria in type 1 diabetes. In contrast, we did not find evidence linking impaired vitamin D metabolism to early GFR loss or the development of hypertension.
Authors: K Makibayashi; M Tatematsu; M Hirata; N Fukushima; K Kusano; S Ohashi; H Abe; K Kuze; A Fukatsu; T Kita; T Doi Journal: Am J Pathol Date: 2001-05 Impact factor: 4.307
Authors: Cortney R Bosworth; Gregory Levin; Cassianne Robinson-Cohen; Andrew N Hoofnagle; John Ruzinski; Bessie Young; Stephen M Schwartz; Jonathan Himmelfarb; Bryan Kestenbaum; Ian H de Boer Journal: Kidney Int Date: 2012-05-30 Impact factor: 10.612
Authors: Debika Nandi-Munshi; Maryam Afkarian; Kathryn B Whitlock; Jamie L Crandell; Ronny A Bell; Ralph D'Agostino; Sharon Saydah; Amy K Mottl; Dana Dabelea; Mary Helen Black; Elizabeth J Mayer-Davis; Catherine Pihoker Journal: Horm Res Paediatr Date: 2017-05-29 Impact factor: 2.852
Authors: Ian H de Boer; Leila R Zelnick; Julie Lin; Debra Schaumberg; Lu Wang; John Ruzinski; Georgina Friedenberg; Julie Duszlak; Vadim Y Bubes; Andrew N Hoofnagle; Ravi Thadhani; Robert J Glynn; Julie E Buring; Howard D Sesso; JoAnn E Manson Journal: Contemp Clin Trials Date: 2018-09-30 Impact factor: 2.226
Authors: Ian H de Boer; Michael C Sachs; Michel Chonchol; Jonathan Himmelfarb; Andrew N Hoofnagle; Joachim H Ix; Robin A Kremsdorf; Yvonne S Lin; Rajnish Mehrotra; Cassianne Robinson-Cohen; David S Siscovick; Michael W Steffes; Kenneth E Thummel; Russell P Tracy; Zhican Wang; Bryan Kestenbaum Journal: Am J Kidney Dis Date: 2014-04-03 Impact factor: 8.860